GLP-1 drugs have ushered in a new era in weight loss.

In just a few years, medications such as semaglutide and tirzepatide, known by the brand names Ozempic, Wegovy, Mounjaro and Zepbound, have gone from niche diabetes treatments to household names, reshaping how America thinks about weight loss.

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, diabetes or another condition. And we expect that number to rise now that one of these drugs, Wegovy, has become available in pill form, increasing its accessibility for many people.

These drugs’ ability to help patients lose anywhere from 15% to 20% of body weight has made them one of the most powerful nonsurgical obesity treatments ever seen.

GLP-1, short for glucagon-like peptide-1, is a hormone your gut normally makes that helps control blood sugar and appetite after eating. It signals the pancreas to release insulin when blood sugar rises and slows how quickly food leaves the stomach, which helps people feel full sooner.

Modern GLP-1 medications are designed to amplify these effects, leading to better blood sugar control and substantial weight loss for many patients.

But success brings a new question that millions of people are confronting: What happens after the weight comes off? And just as importantly, what should patients do when their progress suddenly stalls, even while still on the medication?

As an obesity medicine physician, I’ve seen firsthand how life-changing GLP-1 drug therapy can be for my patients. But I also remind each of them that no medication – GLP-1s included – replaces the foundational importance of nutrition, physical activity, sleep and mental health. These lifestyle pillars are essential for maintaining muscle and bone health, preventing significant weight regain and supporting long-term cardiovascular and metabolic health.

The key is simple but critical: Every weight-loss or health plan........

© The Conversation